Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY survey.

European annals of allergy and clinical immunology·2024
Same author

Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker?

Allergy·2024
Same author

Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness.

European review for medical and pharmacological sciences·2023
Same author

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.

Allergy·2023
Same author

Concomitant Celiac Disease and Wheat Allergy: 2 Case Reports.

Journal of investigational allergology & clinical immunology·2019
Same author

When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation

European annals of allergy and clinical immunology·2019

Related Experiment Video

Updated: Jun 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Specific immunotherapy in asthma: efficacy and safety.

G Passalacqua1, G W Canonica

  • 1Allergy and Respiratory Diseases, University Of Genoa, Genoa, Italy. passalacqua@unige.it

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|January 25, 2011
PubMed
Summary

Specific immunotherapy (SI) for asthma, including subcutaneous (SCIT) and sublingual (SLIT) methods, shows positive results when asthma is controlled. However, SI is not recommended as a standalone therapy for asthma alone.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Area of Science:

  • Allergy and Immunology
  • Respiratory Medicine
  • Pharmacology

Background:

  • The efficacy of specific immunotherapy (SIT) for asthma remains debated, with limited high-quality studies and inconsistent guidelines.
  • Objective pulmonary function parameters have been sporadically assessed in SIT asthma trials.

Purpose of the Study:

  • To evaluate the current evidence for the use of specific immunotherapy (SCIT and SLIT) in managing asthma.
  • To assess the safety and disease-modifying potential of SIT in asthma.
  • To provide recommendations for SIT use in asthma, particularly when associated with rhinitis.

Main Methods:

  • Review of existing high-quality studies and meta-analyses investigating SCIT and SLIT for asthma.
  • Analysis of asthma symptom evaluation and objective pulmonary function data.
  • Assessment of safety data, including adverse events and fatalities.

Main Results:

  • Good quality studies demonstrate positive effects of both SCIT and SLIT on asthma symptoms.
  • Meta-analyses suggest benefits, but are limited by trial heterogeneity.
  • Fatalities associated with SIT are exceptional, especially in Europe over the last two decades.
  • Adequately controlled asthma is a crucial factor for safe and effective SIT.

Conclusions:

  • Both SLIT and SCIT can be beneficial for asthma associated with rhinitis, provided asthma is well-controlled with pharmacotherapy.
  • A measurable clinical benefit in asthma symptoms can be anticipated with SIT in these cases.
  • SIT is not currently recommended as monotherapy for asthma as the sole allergic manifestation.